Medical Scientific Bulletin of Central Chernozemye (Naučno-medicinskij vestnik Centralʹnogo Černozemʹâ)Medical Scientific Bulletin of Central Chernozemye (Naučno-medicinskij vestnik Centralʹnogo Černozemʹâ)1990-472XФедеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации492710.18499/1990-472X-2016-0-65-165-169Original ArticleUSE STRATEGY "THERAPY OBJECTIVES" IN APPOINTING THE DRUG ALTERS THE COURSE OF MULTIPLE SCLEROSIS TAKING INTO ACCOUNT GENETIC FACTORSDutovaT I-SkorohodovA P-UlyanovaO Valatau08@mail.ruVoronezh State Medical UniversityVoronezh City Emergency Hospital №1151220166516516925042020Copyright © 2016, Научно-медицинский вестник Центрального Черноземья2016MS Treatment is one of the most serious problems of practical neurology, however, recently there have been effective ways to influence the course of the disease. This was made possible thanks to the development of modern approaches, based on knowledge of the immunopathogenesis of this disease. At present, for the treatment of MS is widely used drugs that change the course of MS (PITRS); they in any way affect the development of immunopathological processes. In the article the role of studies of immune response genes before selecting PITRS group of drugs.рассеянный склерозпрепараты группы ПИТРСгены иммунного ответа1.Гусев Е.И. Бойко А.Н. Современные подходы к использованию бета-интерферонов в лечении рассеянного склероза. Ж. Неврологии и психиатрии 11(54-59), (2000).2.Звягин А.А., Бавыкина И.А. Практические аспекты дифференциальной диагностики целиакии и гиперчувствительности к глютену /А.А. Звягин А.А., Бавыкина И.А., И.А. Бавыкина // Вопросы детской диетологии. 2015. Т. 13. № 1. С. 37-41.3.Compston A, Coles A: Multiple sclerosis. Lancet 359(9313), 1221 -1231 (2002).4.Cohen BA, Rivera VM: PRISMS: the story of a pivotal clinical trial series in multiple sclerosis. Curr Med Res Opin 26(4), 827-838 (2010).5.Castro-Borrero W, Graves D, Frohman TC, Flores AB, Hardeman P, Logan D, Orchard M, Greenberg B, Frohman EM: Current and emerging therapies in multiple sclerosis: a systematic review. Ther Adv Neurol Disord 5(4), 205-220 (2012).6.Kappos L, Radue EW, O'connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P: A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362(5), 387-401 (2010).7.Lalive PH, Neuhaus O, Benkhoucha M, Burger D, Hohlfeld R, Zamvil SS, Weber MS: Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs 25(5), 401-414 (2011).8.Pelletier D, Hafler DA: Fingolimod for multiple sclerosis. N Engl J Med 366(4), 339-347 (2012).9.Stadelmann С, Wegner С, Bruck W: Inflammation, demyelination, and degeneration -recent insights from MS pathology. Acta 1812(2), 275-282 (2011).10.Sanford M, Lyseng-Williamson KA: Subcutaneous recombinant interferon-beta-la (Rebif(R)): a review of its use in the treatment of relapsing multiple sclerosis. Drugs 71(14), 1865-1891 (2011).